Ph.D. Vanderbilt University, Nashville, TN, USA
MBA, University of MA Amherst
Janssen Pharmaceuticals, Johnson & Johnson, Global Head Dx Innovation, R&D, and Lab Operation, (2015-present)
Abbott Molecular: Divisional VP R&D (2013-2014)
Novartis Oncology: Executive Director (2011-2014)
BM discovery and development
Dx and CDx development
R&D for various disease areas, ID, Oncology, CVM, NeuroSciense, Immunology, etc.
Honors & Awards
2015: Extinguish Alumni Award, National Tsing-Hua Univ. Taiwan
2014: NIH/NCI grant review committee for RFA-CA-13-015 “Cancer Detection, Diagnostics, and Treatment
Technologies for Global Health (UH2/UH3)
2012-2013: Member of Scientific Advisory Council, Genetic Analysis, Life Technologies.
25 publications in peer-review journals
Dx Innovation in the era of big data based PM: Current Trends, Opportunities, and POtential Barriers
The fast evolving and adoption of disruptive technologies has continued to fuel the exponential growth and expansion of big data which has further helped drive the realization of precision medicine and shaped the future of healthcare industry.
The talk will provide overview for the major trend of diagnostic technology innovation as the key drivers of the big data, the opportunities and the barriers for leveraging big data for global commercialization of advanced Dx technologies to drive precision medicine.